Draft:ImmunityBio
 | Review waiting, please be patient.
This may take 5 weeks or more, since drafts are reviewed in no specific order. There are 2,508 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Comment: Remove the excessive citations. One, maybe two, sources are all that is needed to support a fact. Any more than that is excessive. S0091 (talk) 19:24, 25 September 2026 (UTC)
- Comment: In accordance with Wikipedia's Conflict of interest guideline, I disclose that I have a conflict of interest regarding the subject of this article. IsabelleatImmunityBio (talk) 19:13, 25 September 2026 (UTC)
ImmunityBio, Inc. is a U.S.-based biotechnology company headquartered in San Diego, California.[1] The company develops immunotherapies, cell therapies, and vaccine-based platforms for cancer and infectious diseases.[1][2][3] It was founded in 2014 by Dr. Patrick Soon-Shiong and trades on the Nasdaq Global Select Market under the ticker symbol IBRX.[3]
History
[edit]ImmunityBio was established in 2014 by Dr. Patrick Soon-Shiong, as a subsidiary of NantWorks, previously known as NantCell, to develop immunotherapies based on immune activation and cellular immune memory.[3][4] In early 2021, ImmunityBio merged with NantKwest, also founded by Dr. Soon-Shiong.[3][4] The combined company adopted the ImmunityBio name and began trading on Nasdaq under the ticker symbol IBRX.[3][4][5]
On April 22, 2024, the company received FDA approval for Anktiva, its first commercial product.[6][7][8][9]
Richard Adcock serves as President and Chief Executive Officer of ImmunityBio and is a member of the board of directors.[2]
Research
[edit]ImmunityBio’s research includes interleukin-15-based immunotherapies, natural killer cell therapies, and adenovirus-based vaccine platforms. With the exception of Anktiva’s approved use in non-muscle invasive bladder cancer, the company’s other candidates and proposed uses remain investigational.[6][7][8][5][9][10]
References
[edit]- 1 2 Liu, Angus (2024-04-22). "Patrick Soon-Shiong's ImmunityBio bags FDA nod for bladder cancer drug". www.fiercepharma.com. Retrieved 2026-09-25.
- 1 2 Welk, Hannah (2026-03-09). "ImmunityBio's Stock Sees a Huge Boost". Los Angeles Business Journal. Retrieved 2026-09-25.
- 1 2 3 4 5 Idrus, Amirah Al (2020-12-21). "2 Nants become one as Soon-Shiong combines NantKwest, ImmunityBio | Fierce Biotech". www.fiercebiotech.com. Retrieved 2026-09-25.
- 1 2 3 "ImmunityBio, Inc". SEC. Retrieved 2026-09-25.
- 1 2 "Billionaire Soon-Shiong's Biotech Stock Burns Shorts With Surge". Bloomberg.com. Archived from the original on 2026-01-22. Retrieved 2026-09-25.
- 1 2 Singh, Puyaan; Jain, Pratik (2024-04-23). "US FDA approves ImmunityBio's bladder cancer therapy". Reuters. Retrieved 2026-09-25.
- 1 2 Fine, Howard (2026-06-08). "FDA to Review Expanded Use of Cancer Drug". Los Angeles Business Journal. Retrieved 2026-09-25.
- 1 2 Liu, Angus (2025-04-27). "J&J puts ImmunityBio on defense mode in bladder cancer". www.fiercepharma.com. Retrieved 2026-09-25.
- 1 2 "FDA Accepts Supplemental BLA for Nogapendekin Alfa Combo in NMIBC Subtype | CancerNetwork". www.cancernetwork.com. 2026-05-20. Retrieved 2026-09-25.
- ↑ Fabbricatore, Roman (2026-09-25). "Nogapendekin Alfa Plus BCG Exhibits Efficacy Advantage in NMIBC in Situ | CancerNetwork". www.cancernetwork.com. Retrieved 2026-09-25.